Interleukin (IL)-17 inhibitor is a biological therapy approved for moderate to severe psoriasis and psoriatic arthritis. The common adverse events of IL-17 inhibitor include injection site reaction, infections, nasopharyngitis, and headache. However, vitiligo associated with the use of IL-17 inhibitors was rarely reported in the previous literature. Here we described a woman who developed de novo vitiligo after 4 months of IL-17A inhibitor treatment for psoriasis and psoriatic arthritis. Upon discontinuation of IL-17A inhibitor and shifting to a broader T cell inhibitor—cyclosporine, our patient had control of both psoriasis and vitiligo and achieved 75% repigmentation after 3 months of oral cyclosporine without phototherapy. Due to the increasing use of anti-IL-17 biologics in psoriasis patients, clinicians should inquire about vitiligo’s history before treatment and inform patients of the possible adverse effects.
CITATION STYLE
Su, H. J., Chan, Y. P., Shen, P. C., Ku, C. L., & Ng, C. Y. (2023). Anti-IL-17A antibody-associated de novo vitiligo: Case report and review of literature. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.1077681
Mendeley helps you to discover research relevant for your work.